# Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab

> **NCT01009918** · PHASE2 · COMPLETED · sponsor: **University of South Florida** · enrollment: 468 (actual)

## Conditions studied

- Breast Cancer
- Cardiac Toxicity

## Interventions

- **DRUG:** Coreg CR®
- **DRUG:** lisinopril
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT01009918
- **Lead sponsor:** University of South Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2017-08
- **Final completion:** 2018-11
- **Target enrollment:** 468 (ACTUAL)
- **Last updated:** 2021-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01009918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01009918, "Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01009918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*